Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03952806 · ClinicalTrials.gov registry record · Phase 3
Study of BHV-3241 in Participants With Multiple System Atrophy
A Phase 3 study, sponsored by Biohaven Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 421
- Enrollment target
NCT03952806: Completed Phase 3 study, sponsored by Biohaven Pharmaceuticals.
NCT03952806 is a Phase 3 study that has completed, run by Biohaven Pharmaceuticals. The registered enrollment target is 421 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (45% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03952806, a Phase 3 study, has completed, sponsored by Biohaven Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 421 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the efficacy of verdiperstat (BHV-3241) versus placebo in participants with Multiple System Atrophy
Primary Outcome
UMSARS - clinician-rated scale comprised of 4 parts: Part I (Historical Review), Part II (Motor Examination), Part III (Autonomic Examination), Part IV (Global Disability Scale). Modified UMSARS is composed of subset of 9 items from original UMSARS Part I and Part II. Responses are measured on 4-point scale ranged from 0-3, where 0= no/mild impairment, 1= moderate impairment, 2= severe impairment, 3=complete impairment. Total modified UMSARS score is sum of these 9 items, score range from 0 to 2
Interventions
- DRUG Placebo
- DRUG Verdiperstat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 421 participants |
| Start Date | 2019-07-29 |
| Est. Completion | 2022-06-30 |
| Phase | Phase 3 |
What the finished NCT03952806 record still lists
NCT03952806 is an interventional study that assigns participants to a tested intervention. The registered 421 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (45% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03952806 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03952806 about?
NCT03952806 is a clinical study titled "Study of BHV-3241 in Participants With Multiple System Atrophy". The purpose of this study is to compare the efficacy of verdiperstat (BHV-3241) versus placebo in participants with Multiple System Atrophy
What is the current status of trial NCT03952806?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 421 participants. The study started on 2019-07-29. Estimated completion is 2022-06-30.
What interventions are being tested in trial NCT03952806?
The interventions under investigation include: Placebo (DRUG), Verdiperstat (DRUG).
Who is sponsoring clinical trial NCT03952806?
This trial is sponsored by Biohaven Pharmaceuticals, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03952806's enrollment target sits among peer trials
421 890th of 2000 higher than 1,110 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05976763 · 421 participants · Phase 3
Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma
- NCT07114601 · 421 participants · Phase 1
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
- NCT04763356 · 422 participants · NA
Remote Monitoring and Management of Chemotherapy Induced Peripheral Neuropathy
- NCT06837246 · 422 participants · NA
A Clinical Trial to Assess Cognitive Effects of Cognitive Nutritional Supplement in General Population
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI